SEC filing record
Primary Source · SEC.gov

Alkeon Innovation Series, LP - Omicron

Fund Vehicle2026 vintage506(b), 3(c)

Raised

$52M

Investors

54

Min Invest

$1,000,000

AltStreet Verified Issuer badge

Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.

AltStreet Analysis

·

Generated from EDGAR primary sources

Alkeon Innovation Series, LP - Omicron is a Delaware-domiciled pooled investment fund vehicle filed by Alkeon Capital Management, LLC and its affiliated GP, Alkeon Innovation Series GP, LLC. The filing reports $51.8M raised from 54 investors at a $1.0M minimum investment, under combined 506(b) and Investment Company Act 3(c) exemptions; no parent platform or sibling series filings are currently matched in the database.

This filing follows a common institutional private-fund pattern: a Securities Act 506(b) exemption paired with a 3(c) Investment Company Act exclusion, typical of pooled investment vehicles sold to accredited/qualified investors. The $1.0M minimum and ~$960K average check size are consistent with institutional-tier alternative investment offerings rather than retail-oriented structures.

Data Flags

First Sale DateFirst sale date is not disclosed despite $51.8M already reported as sold, and total raise is below the $100M threshold where missing dates are typically expected for large institutional amendments.
ExemptionFiling combines a Securities Act 506(b) exemption with a 3(c) Investment Company Act exclusion, a standard dual-citation pattern for pooled investment funds rather than a per-entity irregularity.
Industry Group / States of SolicitationIndustry group and states of solicitation are left blank, which is a routine optional-field omission rather than a data quality issue.

EDGAR Filing Data

Form D — Primary Source

View on SEC.gov
CIK Number0002164195
Entity NameAlkeon Innovation Series, LP - Omicron
Exemption506(b), 3(c)
Entity Type—
Jurisdiction of OrganizationDelaware
Issuer Address350 Madison Avenue, 20th Floor, New York, NY 10017
Phone(212) 716-6840
Industry / Fund Type—
Securities TypeEquity, Pooled Investment Fund, Other
First Sale Date—
Filing DateNovember 12, 2026
Accession Number0000935836-26-000567
Total Offering Amount—
Total Amount Sold$51,800,000
Total Investors54
Minimum Investment$1,000,000
Offering Duration—
State (Issuer Address)NY
Amendment CountOriginal filing only

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

- Alkeon Innovation Series GP, LLC

Executive Officer · New York, NY

- Alkeon Capital Management, LLC

Executive Officer · New York, NY

Questions About Alkeon Innovation Series, LP - Omicron

Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.

What is Alkeon Innovation Series, LP - Omicron?

Alkeon Innovation Series, LP - Omicron is an issuer that filed a Form D with the SEC on November 12, 2026. The filing claims 506(b), 3(c).

Is Alkeon Innovation Series, LP - Omicron legit?

AltStreet does not rate legitimacy; it reports the public record. Alkeon Innovation Series, LP - Omicron filed a Form D with the SEC on November 12, 2026 claiming 506(b), 3(c). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $51,800,000 sold to 54 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.

Is Alkeon Innovation Series, LP - Omicron registered with or approved by the SEC?

No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Alkeon Innovation Series, LP - Omicron claimed 506(b), 3(c) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.

How much has Alkeon Innovation Series, LP - Omicron raised?

Alkeon Innovation Series, LP - Omicron reported $51,800,000 sold from 54 investors as of the Form D filed November 12, 2026.

Who can invest in Alkeon Innovation Series, LP - Omicron?

The minimum investment accepted from an outside investor is $1,000,000.

What is the minimum investment in Alkeon Innovation Series, LP - Omicron?

The Form D lists $1,000,000 as the minimum investment accepted from any outside investor as of November 12, 2026. Issuers can waive their own minimums, and the figure does not include fees.

Who is selling Alkeon Innovation Series, LP - Omicron and how are they paid?

The Form D names no recipient of sales compensation, which usually means the issuer or its affiliates are placing the securities directly.

Where is Alkeon Innovation Series, LP - Omicron located?

The issuer's address on its SEC filings is 350 Madison Avenue, 20th Floor, New York, NY 10017. Its phone number of record is 212-716-6840. It is organized under the laws of Delaware.

AltStreet Verified Issuer badge

Is this your company or fund?

Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.

Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.